Keith Betts
Education
Ph.D., biostatistics, Harvard University; M.A., biostatistics, University of California, Berkeley; B.S., applied mathematics, University of California, Los Angeles
Summary of Experience
Dr. Betts specializes in the application of advanced biostatistics techniques in the field of health economics and outcomes research (HEOR). He has broad experience developing research strategies in a range of disease areas, including endocrinology, immunology, hematology, neurology, oncology, psychiatry, virology, and women’s health. Dr. Betts has developed and applied new research methods in the fields of individualized medicine methodology, meta-analyses/indirect comparisons, causal inference, Bayesian statistics, missing data problems, and risk prediction. His expertise includes the design and analysis of clinical trials, health economics modeling, indirect comparisons/network meta-analysis, causal inference, psychometrics, survey design, and retrospective database analyses (including administrative claims, electronic medical records, and registry data). Dr. Betts’s work includes developing risk-benefit analyses, cost-effectiveness models, and network meta-analyses for regulatory submission as well as treatment pattern and burden-of-illness research to support the launch of emerging products. His research has been published in peer-reviewed statistical, medical, and health economics journals and presented at clinical and economic research conferences.
-
Safety of Upadacitinib in Immune-Mediated Inflammatory Diseases: Systematic Literature Review of Indirect and Direct Treatment Comparisons of Randomized Controlled Trials
Advances in Therapy, 2024
2024Mysler E, Burmester GR, Saffore CD, Liu J, Wegrzyn L, Yang C, Betts KA, Wang Y, Irvine AD, Panaccione R
-
Comparative effectiveness of erenumab versus rimegepant for migraine prevention using matching-adjusted indirect comparison
Journal of Comparative Effectiveness Research, 2024
2024Mahon R, Tiwari S, Koch M, Ferraris M, Betts KA, Wang Y, Gao S, Proot P
-
Real-world safety of first-line immuno-oncology combination therapies for advanced non-small-cell lung cancer
Future Oncology, 2024
2024Betts KA, Gao S, Ray S, Schoenfeld AJ
-
Tolvaptan and Number Needed to Harm in Autosomal Dominant Polycystic Kidney Disease
Kidney Medicine, 2024
2024 -
Long-Term Temporal Trends of Real-World Healthcare Costs Associated with Nivolumab Plus Ipilimumab and Pembrolizumab Plus Axitinib as First-Line Treatment for Advanced or Metastatic Renal Cell Carcinoma
Oncology and Therapy, 2024
2024Du EX, Betts KA, Wang T, Kitchen SA, He X, Yin X, Guttenplan SB, Beauchamp K, Delgado A, Rosenblatt L
-
A Matching-Adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell Carcinoma
European Urology Oncology, 2023
2023McGregor B, Geynisman DM, Burotto M, Suárez C, Bourlon MT, Barata PC, Gulati S, Huo S, Ejzykowicz F, Blum SI, Tejo VD, Hamilton M, May JR, Du EX, Wu A, Kral P, Ivanescu C, Chin A, Betts KA, Lee CH, Choueiri TK, Cella D, Porta C
-
Impact on Hospitalizations of Long-Term Versus Short-Term Therapy with Sodium Zirconium Cyclosilicate During Routine Outpatient Care of Patients with Hyperkalemia: The Recognize I Study
Expert Review of Pharmacoeconomics and Outcomes Research, 2023
2023Pollack CV, Agiro A, Mu F, Cook EE, Wirtz EL, Young JA, Betts KA, Brahmbhatt YG
-
Impact of benralizumab on asthma exacerbation-related medical healthcare resource utilization and medical costs: results from the ZEPHYR 2 study
Journal of Medical Economics, 2023
2023Chung Y, Maselli DJ, Mu F, Cook EE, Yang D, Young JA, Betts KA, Genofre E, Carstens D
-
Comparative Efficacy of Venetoclax-Based Combination Therapies and Other Therapies in Treatment-Naive Patients With Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy: A Network Meta-Analysis
Value in Health, 2023
2023Li X, Suh HS, Lachaine J, Schuh AC, Pratz K, Betts KA, Song J, Dua A, Bui CN
-
Real-world effectiveness of benralizumab: results from the ZEPHYR 1 Study
Annals of Allergy, Asthma & Immunology, 2022
2022Chung Y, Katial R, Mu F, Cook E, Young J, Yang D, Betts K, Carstens D
-
Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival
Cancer Immunology, Immunotherapy, 2022
2022Weber JS, Poretta T, Stwalley BD, Sakkal LA, Du EX, Wang T, Chen Y, Wang Y, Betts KA, Shoushtari AN
-
Assessment of the relative effectiveness of erenumab compared with onabotulinumtoxinA for the prevention of chronic migraine
Current Medical Research and Opinion, 2022
2022Mahon R, Vo P, Pannagl K, Tiwari S, Heemstra H, Ferraris M, Zhao J, Betts KA, Proot P
-
The Economic Burden of Eosinophilic Gastritis and Eosinophilic Enteritis in the United States
Advances in Therapy, 2022
2022Woolley M, Cook EE, Mu F, Betts KA, Billmyer E, Yim E, Chen J, Wu EQ
-
Costs per patient achieving remission with venetoclax-based combinations in newly diagnosed patients with acute myeloid leukemia ineligible for intensive induction chemotherapy
Journal of Managed Care & Specialty Pharmacy, 2022
2022Choi M, Song J, Bui CN, Ma E, Chai X, Yin L, Betts KA, Kapustyan T, Montez M, LeBlanc TM
-
Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib Versus Sunitinib for Previously Untreated Advanced Renal Cell Carcinoma
Clinical Drug Investigation, 2022
2022Geynisman DM, Burotto M, Porta C, Suarez C, Bourlon MT, Huo S, Del Tejo V, Du EX, Yang X, Betts KA, Choueiri TK, McGregor B
-
Value of Remission in Patients with Rheumatoid Arthritis: A Targeted Review
Advances in Therapy, 2022
2022 -
Temporal trends of adverse events and costs of nivolumab plus ipilimumab versus sunitinib in advanced renal cell carcinoma
Future Oncology, 2022
2022Geynisman DM, Du EX, Yang X, Sendhil SR, Tejo VD, Betts KA, Huo S
-
Benefit-Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis
Rheumatology and Therapy, 2022
2022Conaghan P, Cohen S, Burmester G, Mysler E, Nash P, Tanaka Y, Rigby W, Patel J, Shaw T, Betts KA, Patel P, Liu J, Sun R, Fleischmann R
-
Long-Term Benefit-Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-Analysis
Dermatology and Therapy, 2022
2022Armstrong AW, Soliman AM, Betts KA, Wang Y, Gao Y, Stakias V, Puig L
-
Real-World Management of Hyperkalemia in the Emergency Department: An Electronic Medical Record Analysis
Advances in Therapy, 2022
2022Davis J, Israni R, Betts KA, Mu F, Cook EE, Anzalone D, Szerlip H, Yin L, Uwaifo GI, Wu EQ
-
CKD Progression and Economic Burden in Individuals with CKD Associated with Type 2 Diabetes
Kidney Medicine, 2022
2022Mullins CD, Pantalone KM, Betts KA, Song J, Wu A, Chen Y, Kong SX, Singh R
-
Network meta-analysis of nivolumab plus ipilimumab in the second-line setting for advanced hepatocellular carcinoma
Journal of Comparative Effectiveness Research, 2021
2021Parikh ND, Marshall A, Betts KA, Song J, Zhao J, Yuan M, Wu A, Huff KD, Kim R
-
A Matching-Adjusted Indirect Comparison of Upadacitinib Versus Tofacitinib in Adults with Moderate-to-Severe Rheumatoid Arthritis
Rheumatology and Therapy, 2021
2021 -
Inpatient Management and Post-Discharge Outcomes of Hyperkalemia
Hospital Practice, 2021
2021Davis J, Israni R, Mu F, Cook E, Szerlip H, Uwaifo G, Fonseca V, Betts K
-
Real-World Treatment Profiles, Clinical Outcomes, and Healthcare Resource Utilization of Patients with Migraine Prescribed Erenumab: A Multicenter Chart-Review Study of US Headache Centers
Neurology and Therapy, 2021
2021Faust E, Pivneva I, Yang K, Betts KA, Ahmed Z, Joshi S, Hogan R, Blumenfeld A, Schim J, Feoktistov A, Carnes K, Bensink M, Wu EQ, Chou DE, Chandler D
-
Comparative Efficacy and Relative Ranking of Biologics and Oral Therapies for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis
Dermatology and Therapy, 2021
2021Armstrong AW, Soliman AM, Betts KA, Wang Y, Gao Y, Puig L, Augustin M
-
Comparative safety and benefit-risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis: A network meta-analysis of clinical trial data
Journal of the American Academy of Dermatology, 2021
2021Shear NH, Betts KA, Soliman AM, Joshi A, Wang Y, Zhao J, Gisondi P, Sinvhal R, Armstrong AW
-
Determinants of Hyperkalemia Progression Among Patients with Mild Hyperkalemia
Advances in Therapy, 2021
2021Israni R, Betts KA, Mu F, Davis J, Wang J, Anzalone D, Uwaifo GI, Szerlip H, Fonseca V, Wu E
-
Prevalence of Metabolic Acidosis Among Patients with Chronic Kidney Disease and Hyperkalemia
Advances in Therapy, 2021
2021Cook EE, Davis J, Israni R, Mu F, Betts KA, Anzalone D, Yin L, Szerlip H, Uwaifo GI, Fonseca V, Wu EQ
-
Model of Short- and Long-Term Outcomes of Emicizumab Prophylaxis Treatment for Persons with Hemophilia A
Journal of Managed Care & Specialty Pharmacy, 2020
2020Zhou ZY, Raimundo K, Patel A, Han S, Ji Y, Fang H, Zhong J, Betts K, Mahajerin A
-
Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-Analysis
Advances in Therapy
2020Pope J, Sawant R, Tundia N, Du EX, Qi CZ, Song Y, Tang P, Betts KA
-
Postdischarge Health Care Costs and Readmission in Patients With Hyperkalemia-Related Hospitalizations
Kidney International Reports, 2020
2020 -
Number needed to treat and cost per remitter for biologic treatments of Crohn's disease in Japan
Journal of Medical Economics, 2020
2020Ueno F, Doi M, Kawai Y, Ukawa N, Cammarota J, Betts KA
-
Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysis
JAMA Dermatology, 2020
2020Armstrong AW, Puig L, Joshi A, Skup M, Williams D, Li J, Betts KA, Augustin M
-
Economic burden associated with tuberous sclerosis complex in patients with epilepsy
Epilepsy & Behavior, 2020
2020Betts KA, Stockl KM, Yin L, Hollenack K, Wang MJ, Yang X
-
US cost–effectiveness of polatuzumab vedotin, bendamustine and rituximab in diffuse large B-cell lymphoma
Journal of Comparative Effectiveness Research, 2020
2020Betts KA, Thuresson PO, Felizzi F, Du EX, Dieye I, Li J, Schulz M, Masaquel AS
-
Economic Burden of Switching to Different Biologic Therapies Among Tumor Necrosis Factor Inhibitor-Experienced Patients with Psoriatic Arthritis
Rheumatology and Therapy, 2019
2019 -
Indirect Treatment Comparison of Nivolumab Versus Observation or Ipilimumab as Adjuvant Therapy in Resected Melanoma Using Pooled Clinical Trial Data
Advances in Therapy, 2019
2019Freeman M, Betts KA, Jiang S, Du EX, Gupte-Singh K, Lu Y, Rao S, Shoushtari AN
-
The prevalence of hyperkalemia in the United States
Current Medical Research and Opinion. 2018 Jun;34(6):971-978
2018 -
Comparison of Adalimumab and Etanercept for the Treatment of Moderate to Severe Psoriasis: An Indirect Comparison Using Individual Patient Data from Randomized Trials
Value in Health. Jan 2018;21(1):1-8
2018Papp KA, Yang M, Sundaram M, Jarvis J, Betts KA, Bao Y, Signorovitch JE
-
Number needed to treat and costs per responder among biologic treatments for moderate-to-severe psoriasis: a network meta-analysis
Current Medical Research and Opinion. Apr 23 2018:1-9
2018Armstrong AW, Betts KA, Signorovitch JE, Sundaram M, Li J, Ganguli AX, Wu EQ
-
Number needed to treat and costs per responder among biologic treatments for moderate to severe psoriasis
Current Medical Research and Opinion. 2018 Jul;34(7):1325-1333
2018Armstrong AW, Betts KA, Signorovitch JE, Sundaram M, Li J, Wu EQ
-
Concomitant Use of Psychotropic Medication With Stimulants for the Treatment of ADHD in Children and Adolescents: A Retrospective Insurance Claims Study in the United States
Journal of Attention Disorders, July 1, 2018
2018Zhou Z, Betts KA, Bocharova I, Kinrich D, Spalding WM
-
Elotuzumab Plus Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Extended 4-Year Follow-Up and Analysis of Relative Progression-Free Survival From the Randomized ELOQUENT-2 Trial
Cancer. 2018 Oct 15;124(20):4032-4043
2018Dimopoulos MA, Lonial S, Betts KA, Chen C, Zichlin ML, Brun A, Signorovitch JE, Makenbaeva D, Mekan S, Sy O, Weisel K, Richardson PG
-
Real-World Outcomes of Acute Ischemic Stroke Treatment with Intravenous Recombinant Tissue Plasminogen Activator
Journal of Stroke and Cerebrovascular Diseases. Sep 2017;26(9):1996-2003
2017Betts KA, Hurley D, Song J, Sajeev G, Guo J, Du EX, Paschoalin M, Wu EQ
-
Comparative efficacy of long-acting beta2-agonists as monotherapy for chronic obstructive pulmonary disease: a network meta-analysis
International Journal of Chronic Obstructive Pulmonary Disease. 2017;12:367-381
2017Donohue JF, Betts KA, Du EX, Altman P, Goyal P, Keininger DL, Gruenberger JB, Signorovitch JE
-
Poor early response to methotrexate portends inadequate long-term outcomes in patients with moderate-to-severe psoriasis: Evidence from 2 phase 3 clinical trials
Journal of the American Academy of Dermatology. Dec 2017;77(6):1030-1037
2017Gordon KB, Betts KA, Sundaram M, Signorovitch JE, Li J, Xie M, Wu EQ, Okun MM
-
Benefit-risk trade-offs for treatment decisions in moderate-to-severe rheumatoid arthritis: focus on the patient perspective
Rheumatology International. Jun 16 2017:1-12
2017 -
Number needed to treat and costs per responder among biologic treatments for moderate-to-severe plaque psoriasis in Japan
Journal of Dermatological Treatment. Feb 2018;29(1):24-31
2017 -
Real-world costs of ischemic stroke by discharge status
Current Medical Research and Opinion. Feb 2017;33(2):371-378
2017Mu F, Hurley D, Betts KA, Messali AJ, Paschoalin M, Kelley C, Wu EQ
-
Comparative Effectiveness of Adalimumab versus Secukinumab for the Treatment of Psoriatic Arthritis: A Matching-Adjusted Indirect Comparison
Rheumatology Therapeutics. Jul 31 2017
2017 -
Systematic Literature Review and Meta-analysis of Tumor Necrosis Factor-Alpha Experienced Rheumatoid Arthritis
Clinical Therapeutics. Aug 2017;39(8):1680-1694 e1682
2017Wells AF, Curtis JR, Betts KA, Douglas K, Du EX, Ganguli A
-
Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis after Etanercept Discontinuation in the United Kingdom, France, and Germany
Clinical Therapeutics. Aug 2017;39(8):1618-1627
2017Li N, Betts KA, Messali AJ, Skup M, Garg V
-
Effect of Adalimumab on Visual Functioning in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis in the VISUAL-1 and VISUAL-2 Trials
JAMA Ophthalmol. Jun 01 2017;135(6):511-518
2017Sheppard J1, Joshi A, Betts KA, Hudgens S, Tari S, Chen N, Skup M, Dick AD
-
Corticosteroid-Related Adverse Events Systematically Increase with Corticosteroid Dose in Noninfectious Intermediate, Posterior, or Panuveitis: Post Hoc Analyses from the VISUAL-1 and VISUAL-2 Trials
Ophthalmology. Dec 2017;124(12):1799-1807
2017Suhler EB, Thorne JE, Mittal M, Betts KA, Tari S, Camez A, Bao Y, Joshi A
-
Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid Arthritis
Clinical Therapeutics, 2016 05; 38(5): 1205-1216. e-pub ahead of print 2016/04/06
2016 -
Network Meta-Analysis and Cost Per Responder of Tumor Necrosis Factor-alpha and Interleukin Inhibitors in the Treatment of Active Ankylosing Spondylitis
Rheumatology and Therapy, 2016 07: 1-14
2016Betts KA, Griffith J, Song Y, Mittal M, Joshi A, Wu EQ, Ganguli A.
-
ASAS40 and ASDAS clinical responses in the ABILITY-1 clinical trial translate to meaningful improvem(1)
Rheumatology (Oxford). 2016 Jan;55(1):80-8. doi: 10.1093/rheumatology/kev267. Epub 2015 Aug 27
2016Van der Heijde D, Joshi A, Pangan AL, Chen N, Betts KA, Mittal M, Bao Y.
-
Economic Burden of Switching to a Non-Tumor Necrosis Factor Inhibitor Versus a Tumor Necrosis Factor Inhibitor Biologic Therapy among Patients with Rheumatoid Arthritis
Advances in Therapy, 2016 05; 33(5): 807-823. e-pub ahead of print 2016/04/17
2016 -
Comparative efficacy and safety of daclatasvir/asunaprevir versus IFN-based regimens in genotype 1b hepatitis C virus infection
J Comp Eff Res. 2015 Nov;4(6):593-605. doi: 10.2217/cer.15.33. Epub 2015 Jul 10.
2015Signorovitch JE, Betts KA, Yan Y, Sorg R, Li J, Behl AS, Kalsekar A.
-
Comparative efficacy of biological treatments for moderate-to-severe psoriasis: a network meta-analysis adjusting for cross-trial differences in reference arm response
Br J Dermatol. 2015 Feb;172(2):504-12. doi: 10.1111/bjd.13437. Epub 2015 Jan 21.
2015Signorovitch JE, Betts KA, Yan YS, LeReun C, Sundaram M, Wu EQ, Mulani P.
-
Identifying patient subgroups who benefit most from a treatment: using administrative claims data to uncover treatment heterogeneity
J Med Econ. 2012; 15(6):1078-87
2012Erder MH, Signorovitch JE, Setyawan J, Yang H, Parikh K, Betts KA, Xie J, Hodgkins P, Wu EQ
-
Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials
Curr Med Res Opin. 2011 Jun;27(6):1263-71. Epub 2011 Apr 28
2011Signorovitch J, Wu EQ, Betts K, Parikh K, Kantor E, Guo A, Bollu V, Williams D, Wei L, DeAngelo D
-
June 20, 2024
-
April 11, 2024
-
February 1, 2024
-
October 23, 2023
-
April 5, 2022
-
March 29, 2022
-
July 20, 2021
-
June 4, 2021